About Us
Reboot Rx is a nonprofit dedicated to advancing affordable cancer treatments by repurposing generic drugs. The organization synthesizes and evaluates published clinical evidence on repurposed generic drugs for cancer in consultation with clinical experts, advances new clinical research through strategic partnerships, and develops and disseminates evidence-based information for clinicians, health systems, and other healthcare decision-makers.
Reboot Rx does not manufacture or sell drugs and does not profit from the sale of drugs.
Our Process: Identifying the repurposing potential of aspirin for colorectal cancer
Aspirin is not FDA-approved for the treatment of colorectal cancer. This page is intended for informational purposes only and is not intended to provide medical advice and should not be relied upon in that regard. Clinicians should make individual prescribing decisions for their patients based on the patient’s clinical presentation and the clinician’s own medical decision-making.
Identification of emerging evidence
Through our active network of clinical and research experts, we became aware of forthcoming data on aspirin in patients with PIK3CA-mutated colorectal cancer. This prompted a structured review of the literature evaluating aspirin in this subpopulation of colorectal cancer.
Comprehensive evidence assessment
Using our AI-enabled evaluation framework, our team of biomedical scientists reviewed the totality of existing evidence on aspirin in this patient subpopulation, considering the:
Strength and consistency of the clinical evidence
Magnitude of unmet need
Drug accessibility and cost
Feasibility of clinical implementation
Based on this assessment, aspirin for patients with stage II–III PI3K-altered colorectal cancer was identified as a priority area of focus.
Evaluation of clinical context
With clinical experts, we evaluated current practice patterns, biomarker testing considerations, awareness of the existing evidence, and barriers to clinical use.
While our review was underway, clinical guidelines evolved:
In April 2025, the NCCN Guidelines for colon and rectal cancers added a recommendation for daily aspirin (100–162 mg) as a treatment option following definitive treatment for patients with stage II–III colon and rectal cancer with a confirmed PIK3CA mutation.
In March 2026, an update to these guidelines expanded the patient population that could consider aspirin to include patients with somatic PI3K alterations (variants in the PIK3CA, PIK3R1, and PTEN genes).
Together, these factors led us to collate the published studies and information on aspirin for patients with PI3K-altered colorectal cancer and create this clinician resource to support review of the evidence.
Learn more about Reboot Rx:
Subscribe to receive updates on Reboot Rx and our work on aspirin.
Reboot Rx is a registered 501(c)(3) nonprofit organization. Reboot Rx does not manufacture or sell drugs, and does not profit from the sale of drugs. Information provided on the Reboot Rx website (the “Information”), available at http://rebootrx.org (the “Site”), is intended for U.S. healthcare professionals only and not intended for patients. Information available on this Site is intended for informational purposes only and is not intended to provide medical advice and should not be relied upon in that regard. Reboot Rx provides this Information as an educational resource for the benefit of the medical community. The Information on this website has not been evaluated by the Food and Drug Administration. Reboot Rx is not a medical provider or health care facility and does not practice medicine. It thus can neither diagnose any disease or disorder, nor endorse or recommend any specific medical treatments. Nothing on this Site constitutes medical advice, recommendations as to the suitability of any specific product, service or information, or diagnoses for any medical condition. Any materials made available via the Site are provided for convenience and informational purposes only. Any clinician seeking to apply or consult the content and/or derivative sources on this website must use their independent medical judgment in the context of the individual clinical circumstances to determine any patient’s care or treatment.